PREVIOUS
✖
COVAXIN
December 12 , 2020
1368 days
683
0
- Bharat Biotech applied for the emergency use authorisation to the Drugs Controller General of India (DGCI) for its indigenously developed COVID-19 vaccine ‘COVAXIN’.
- With this step, Bharat Biotech, based in Hyderabad, has become the third applicant of the vaccine after Pfizer and Serum Institute of India to apply for the approval of emergency use in India.
- COVAXIN has been indigenously developed by Bharat Biotech in joint collaboration with the Indian Council of Medical Research (ICMR).
- The Indian arm of Pfizer became the first applicant in India only after getting clearance in the United Kingdom and Bahrain.
- Serum Institute of India became the second firm to apply for the emergency approval.
- Serum Institute has applied for the approval of the COVIDSHIELD vaccine.
- It has been co-developed by Oxford University and pharma company AstraZeneca.
Leave a Reply
Your Comment is awaiting moderation.